# A Study of Oral Insulin to Reduce Liver Fat Content in Type 2 Diabetes Patients With Nonalcoholic Steatohepatitis (NASH)

> **NCT04616014** · PHASE2 · COMPLETED · sponsor: **Oramed, Ltd.** · enrollment: 7 (actual)

## Conditions studied

- Nonalcoholic Steatohepatitis (NASH)

## Interventions

- **DRUG:** ORMD-0801 QD

## Key facts

- **NCT ID:** NCT04616014
- **Lead sponsor:** Oramed, Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-03-01
- **Primary completion:** 2022-07-01
- **Final completion:** 2022-09-15
- **Target enrollment:** 7 (ACTUAL)
- **Last updated:** 2024-03-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04616014

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04616014, "A Study of Oral Insulin to Reduce Liver Fat Content in Type 2 Diabetes Patients With Nonalcoholic Steatohepatitis (NASH)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04616014. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*